Treatment Intensification Benefits Extend Beyond High-Risk EGFR-Mutated NSCLC

July 28, 2026 | Ashling Wahner

Frontline treatment intensification improves progression-free survival (PFS) and overall survival (OS) in patients with EGFR-mutated non–small cell lung cancer (NSCLC), a benefit that is not confined to only patients with poor prognostic features, according to Lyudmila Bazhenova, MD, FASCO.1 However, she noted that identifying which patients can safely receive osimertinib (Tagrisso) alone remains unclear.

In a presentation at the 27th Annual International Lung Cancer Congress®, Bazhenova traced the evolution of frontline therapy through 4 treatment eras, compared the 2 FDA-approved first-line intensification regimens across trials, and challenged the assumption that intensification should be reserved for patients with high-risk disease features.

Bazhenova is a clinical professor of medicine at the University of California San Diego Moores Cancer Center.

How have frontline therapy outcomes in EGFR-mutated NSCLC changed over the years, and which intensification strategies are FDA approved?

Bazhenova opened by tracing treatment outcomes across 4 eras. In the pre-biomarker period, when EGFR TKIs were given to unselected patients, the median OS was approximately 6.7 months. The phase 3 IPASS trial (NCT00322452) established first-generation EGFR TKIs as a standard of care, and real-world data with the EGFR TKI afatinib (Gilotrif) showed an extended median OS of 26.6 months (95% CI, 13.7-not evaluable).2

Then, in the phase 3 FLAURA trial (NCT02296125), the third-generation TKI osimertinib extended the median OS to 38.6 months (95% CI, 34.5-41.8), and intensification with osimertinib plus platinum-pemetrexed in the phase 3 FLAURA2 study (NCT04035486) has pushed the median OS to 47.5 months (95% CI, 41.0-NC).3,4 Median PFS was also extended with treatment intensification.

Three frontline regimens are FDA approved for the treatment of patients with EGFR-mutated NSCLC: osimertinib, osimertinib plus chemotherapy, and amivantamab-vmjw (Rybrevant) plus lazertinib (Lazcluze), which were approved based on data from the FLAURA, FLAURA2, and phase 3 MARIPOSA (NCT04487080) trials, respectively.5-7

Because no head-to-head comparisons exist between the FDA-approved first-line regimens for advanced EGFR-mutated NSCLC, Bazhenova presented a cross-trial analysis of FLAURA2 and MARIPOSA. Osimertinib monotherapy performed similarly as the control across both studies. In the FLAURA2 trial, osimertinib plus platinum-pemetrexed produced a median PFS of 25.5 months (95% CI, 24.7-not calculable; HR vs osimertinib monotherapy, 0.62; 95% CI, 0.49-0.79; P < .001), and the OS data favored the combination (HR, 0.77; 95% CI, 0.61-0.96; P = .02).4,8 In the MARIPOSA study, amivantamab plus lazertinib produced a median PFS of 23.7 months (95% CI, 19.1-27.7; HR, 0.70; 95% CI, 0.58-0.85; P < .0002), with a median OS that was not reached (HR, 0.75; 95% CI, 0.61-0.92; P = .0048).9

Toxicity profiles differentiate these first-line regimens, according to Bazhenova.

“We are faced with the decision of, if we are intensifying: How do we decide what we intensify with, and how do we manage the toxicity profile?” she said, framing the central question as whether added toxicity justifies improved efficacy seen with more intense regimens.

Why intensify EGFR-targeted first-line NSCLC therapy when some patients have good outcomes with osimertinib monotherapy?

A subset of patients does well with osimertinib alone, Bazhenova noted. In FLAURA, 28% of patients continued to receive osimertinib for at least 36 months.3

“When I start a patient on osimertinib, I have no ability to predict whether my patient will be… [receiving] osimertinib for a long time,” Bazhenova said. “The reason to intensify is because we don’t know which of our patients are going to do well.”

However, Bazhenova’s second argument in favor of up-front treatment intensification is that the route to second-line therapy is not guaranteed. In FLAURA, 22% of patients in the osimertinib arm died before receiving subsequent anticancer therapy.

Should EGFR-directed NSCLC treatment intensification be reserved for patients with poor prognostic features?

Because intensification increases toxicity, it has been argued that this approach should be limited to patients with poor prognostic features. Bazhenova challenged that reasoning across 3 biomarkers.

Among patients with baseline central nervous system (CNS) metastases, the HR for PFS favored intensification at 0.47 (95% CI, 0.33-0.66) in FLAURA2.8,9 However, among patients without CNS metastases at baseline, the HR remained at 0.75 (95% CI, 0.55-1.03).

“I intensify regardless of the presence or absence of brain metastases,” Bazhenova said.

This pattern held for circulating tumor DNA (ctDNA) status. In MARIPOSA, patients without detectable baseline ctDNA positivity had a HR of 0.72 (95% CI, 0.47-1.10; P = .132) favoring amivantamab/lazertinib, compared with 0.68 (95% CI, 0.53-0.86; P = .002) among ctDNA shedders.10

“Even the patients who do not shed ctDNA might benefit from intensification,” Bazhenova suggested.

The data regarding treatment intensification decision-making based on TP53 mutation status are less clear-cut, but some patterns have emerged. In MARIPOSA, among patients with TP53 wild-type disease, the HR favored amivantamab/lazertinib at 0.75 (95% CI, 0.52-1.07; P = .114), vs 0.65 (95% CI, 0.48-0.87; P = .003) favoring the combination among those with TP53 co-mutated disease.

What questions about treatment intensification in EGFR-mutated NSCLC remain unanswered?

Bazhenova concluded that osimertinib monotherapy remains appropriate for patients with poor performance status and for those who decline intensification because of toxicity profiles associated with intensified regimens. She acknowledged a likely greater magnitude of benefit in patients with poor prognostic factors but maintained that patients without those features also benefit.

Two questions remain unanswered, she said. The first is how to prospectively identify the patients who will benefit from osimertinib alone. The second concerns the duration of treatment intensification.

“If I intensify, do I need to intensify forever?” she asked? “Can I intensify for 2 or 3 months and then back down and continue with osimertinib monotherapy?”

References

Bazhenova L. First-line therapy for classical EGFR mutations. Presented at: 27th Annual International Lung Cancer Congress; July 24-25, 2026; Huntington Beach, California.

Qureshi S, Boily G, Boulanger J, et al. Advanced lung cancer patients’ use of EGFR tyrosine kinase inhibitors and overall survival: real-world evidence from Quebec, Canada. Curr Oncol. 2022;29(11):8043-8073. doi:10.3390/curroncol29110636

Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41-50. doi:10.1056/NEJMoa1913662

Planchard D, Jänne PA, Kobayashi K, et al. First-line osimertinib + chemotherapy versus osimertinib monotherapy in EGFRm advanced NSCLC: FLAURA2 final overall survival. Presented at: International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer; September 6-9, 2025; Barcelona, Spain. Abstract 1956.

US FDA approves Tagrisso as 1st-line treatment for EGFR-mutated non-small cell lung cancer. News release. AstraZeneca. April 18, 2018. Accessed July 24, 2026. https://www.astrazeneca.com/media-centre/press-releases/2018/us-fda-approves-tagrisso-as-1st-line-treatment-for-EGFR-mutated-non-small-cell-lung-cancer.html#

FDA approves osimertinib with chemotherapy with chemotherapy for EGFR-mutated non-small cell lung cancer. FDA. February 16, 2024. Accessed July 24, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-osimertinib-chemotherapy-egfr-mutated-non-small-cell-lung-cancer

Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. News release. Johnson & Johnson. August 20, 2024. Accessed July 24, 2026. https://www.investor.jnj.com/news/news-details/2024/RYBREVANT-amivantamab-vmjw-plus-LAZCLUZE-lazertinib-approved-in-the-U.S.-as-a-first-line-chemotherapy-free-treatment-for-patients-with-EGFR-mutated-advanced-lung-cancer/default.aspx

Planchard D, Jänne PA, Cheng Y, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2023;389(21):1935-1948. doi:10.1056/NEJMoa2306434

Rybrevant (amivantamab-vmjw) + Lazcluze (lazertinib) first-line EGFR+ mNSCLC (MARIPOSA) efficacy & safety. Johnson & Johnson. Updated May 2026. Accessed July 24, 2026. https://www.rybrevanthcp.com/clinical-data/mariposa/

Felip E, Cho BC, Gutiérrez V, et al. Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: a secondary analysis from the phase 3 MARIPOSA study. J Clin Oncol. 2024;42(suppl 16):8504. doi:10.1200/JCO.2024.42.16_suppl.8504